Expert Review of

Editorial Advisory Panel

Overseeing the editorial content and development of Expert Review of Proteomics is an Editorial Advisory Board, composed of many of the world's leading experts in the field, drawn from both research and academia.

Albala JS, UC Davis School of Medicine, CA, USA

Apweiler R, European Institute, Cambridge, UK Dr Rolf Apweiler studied Biology with an emphasis on Molecular Biology and at the University of Heidelberg, Germany and the University of Bath, UK. He worked between 1991-1994 in drug discovery at Boehringer Mannheim and has been involved in the Swiss-Prot project since 1987. He co- ordinates the Swiss-Prot knowledgebase group at the EBI since 1994, and started the TrEMBL, InterPro, Proteome analysis and CluSTr projects at the EBI. Since autumn 2001 he is also in charge of the EMBL nucleotide sequence database and started in 2002 the merge of the Swiss-Prot and TrEMBL projects with the PIR to UniProt. Dr Apweiler is heading a team of currently 100 biologists and programmers responsible for the UniProt, InterPro, Proteome analysis, CluSTr and EMBL nucleotide sequence database projects at the EBI. Rolf Apweiler's main research interests are focused on integrating heterogenous functional genomic and proteomic data resources with the main and nucleotide sequence databases, and automation of classification and annotation of protein sequences.

Blackburn J, Cambridge University, Cambridge, UK Professor Blackburn received a doctorate and an honours degree in chemistry from the University of Oxford. Following his Doctorate, Professor Blackburn carried out post-doctoral research with Professor Fersht at the Centre for Protein Engineering in Cambridge. He then took up a Royal Society University Research Fellowship in the Biochemistry Department, University of Cambridge and was a Fellow of Fitzwilliam College, Cambridge. He has recently moved to take up a Chair in Biochemistry in the Department of Biotechnology, University of the Western Cape, Cape Town. His academic research has ranged from the synthesis of novel enzyme substrates and inhibitors, through molecular biology, protein chemistry and enzymology to the development of new display and array methodologies and the directed evolution of novel . He has published extensively in highly qualified peer reviewed scientific journals and was a founder and the Chief Scientific Officer of Sense Proteomic Ltd. Following acquisition, he is now the Chief Scientist of Procognia Ltd.

Borchers C, University of North Carolina, NC, USA

Burchmore R, University of Glasgow, UK Dr Burchmore is Head of Proteomics at the Sir Henry Wellcome Functional Genomics Facility in the Institute of Biomedical and Life Sciences, University of Glasgow. He studied parasitology and biochemistry at the University of London, completing a PhD in 1993. This was followed by a postdoctoral fellowship at Oregon Health Sciences University, USA, and further postoctoral posts in the UK. Dr Burchmore has a long standing interest in the role of membrane proteins in cellular nutrient acquisition, and has published extensively in high quality journals. Current research interests focus on the application of proteomic technologies to membrane proteins, to elucidate the role of membrane transporters in pathogen virulence and drug resistance.

Chen T, University of Southern California, CA, USA Dr Chen is an assistant professor of biological sciences, computer science and mathematics at the University of Southern California. He is an Alfred P. Sloan Fellow. He received his PhD degree in computer science from the State University of New York at Stony Brook in 1997. He was a lecturer of genetics and research fellow at Harvard University from 1997 to 2000. His research focuses on (1) the analysis of protein interactions, functions and pathways, (2) the protein identification and sequencing via HPLC-tandem mass spectrometry, and (3) the analysis of Human SNPs.

Cho WC, Queen Elizabeth Hospital, Hong Kong Dr William Chi-shing Cho is a scientific officer at the Department of Clinical Oncology in Queen Elizabeth Hospital. He embarked his research work with biochemistry and Chinese medicine. After joining Queen Elizabeth Hospital, his main research interests have been focusing on local prevalent cancers such as nasopharyngeal carcinoma and lung cancer. Dr Cho’s recent work was featured at utilizing high-throughput mass spectrometry technology to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. Dr Cho is an editor on several scientific journals and has published more than 60 articles covering cancer biomarkers discovery, oncoproteomics, chronic diseases’ pharmacology and Chinese medicine in publications including Clin Chem, Clin Cancer Res, Ann Oncol, J Cell Biochem, Mol Cancer, etc. He has also published books and articles on the topics of cancer encyclopedia, cancer biomarkers and proteomics methodologies with Springer and Humana Press.

Godovac Zimmermann J, University College London, United Kingdom Jasminka Godovac Zimmermann is Professor at University College London, UK and Head of the Molecular Dynamics Group. She is protein chemist trained at Max-Planck Institute for Biochemistry in Martinsried, Germany. Subsequently, she worked at the Australian National University in Canberra, Australia and the University of Mainz Institute for Molecular Biotechnology, Jena, Germany. She works on functional phosphoproteomics of signal transduction by membrane receptors. Her interest is shifting to cancer proteomics and the complexity of eukaryotic proteomics. She is an author of over 100 research papers and reviews and over 100 presentations. She is also a co- founder of two biotechnology companies.

Grant S, Wellcome Trust Sanger Institute, Cambridge, UK

Joos T, University of Tuebingen, Germany Dr Thomas Joos is head of the biochemistry department of the NMI Natural and Medical Sciences Institute at the University of Tuebingen. The NMI is a research foundation supported by the Ministry of Commerce of the Baden- Württemberg state. The Institute is associated with the University of Tuebingen. Scientists in the areas of applied and theoretical physics, chemistry, physical chemistry, biology and biochemistry are experienced in system analysis and problem solution for industrial clients. The R&D activities at the NMI are characterised by their multidisciplinary approach. Dr Joos has been with the NMI since 1998, where he has been responsible for protein microarray technology. Prior to joining the NMI, Dr Joos did his postdoctoral research in the laboratory of Prof. Peter Hausen at the Max-Planck-Institute of Developmental Biology, Department of Cell biology, researching cell-cell and cell-matrix interaction during early embryogenesis of Xenopus laevis. Dr Joos studied Biochemistry at the University of Tuebingen. He received his Ph.D. 5 during early embroygenesis of degree in 1985 on integrin- Xenopus laevis.

Kondo T, National Cancer Center Research Institute, Japan

Liotta LA, George Mason University, VA, USA Dr Lance A. Liotta, M.D., Ph.D. is Chief of the Laboratory of Pathology and Chief of the Section of Tumor Invasion and Metastases in the Division of Clinical Sciences, National Cancer Institute, NIH. He is the former Deputy Director for Intramural Research, NIH. He received his M.D./ Ph.D. at Case Western Reserve University in 1976. Dr Liotta's Ph.D. is in Biomedical Engineering. Dr Liotta served his residency training in anatomic pathology at the NIH in the Laboratory of Pathology. He became Chief of the same Laboratory in 1982. Dr Liotta was one of the first scientists to investigate the process of tumor invasion and metastasis at a molecular level. Dr Liotta and colleagues in the Laboratory of Pathology invented Laser Capture Microdissection (LCM) which is commercialized and used in more than 1000 labs worldwide. LCM has been applied to make broad discoveries in genomics, functional genetics, and is now extending into tissue proteomics. In partnership with Dr Emanuel Petricoin of the FDA, Dr Liotta initiated the first joint initiative between the FDA and the NCI to develop new technology for the discovery of proteins and the profiling of signal pathways in actual human tissue. He and Dr Petricoin were the first to use "Artificial Intelligence" type learning algorithms to discover disease-associated proteomic patterns in the serum of patients that correlates with the presence of early stage ovarian and prostate cancer (Petricoin et al Lancet 2002, 359:572-577). They were the first to propose and demonstrate that the low molecular weight blood proteome is a treasure trove of diagnostic and physiologic information. The information content is contained in 1000s of clipped and modified proteins and peptides shed from every tissue and cellular compartment.

Mayer B, University of Connecticut Health Center, CT, USA

Morozov V, George Mason University, USA

Nakamura K, Yamaguchi University School of Medicine, Japan Kazuyuki Nakamura is Professor and Chairman of Department of Biochemistry and Biomolecular Recognition, Yamaguchi University School of Medicine, Japan. He served as Director of Central Laboratory for Biomedical Research and Education from 1992 to 2000, Director of University Library of Yamaguchi University from 2001 to 2003, and now he is Associate Dean of School of Medicine. He is serving for the promotion of proteomics as HUPO and AOHUPO Council Members and Co-Chair of Human Disease Glycomics Proteome Initiative (HGPI). He is active in Education and Training of domestic young scientists for proteomics as President of Japanese Electrophoresis Society and Vice-President of Japan HUPO. He is interested in ‘expression proteomics’ for hepatitis C virus-related hepatocellular carcinoma and pancreatic cancer using 2D gel electrophoresis and tandem mass spectrometry, and in ‘ functional proteomics’ using protein chips for high throughput proteomics. His interest is shifting to cancer immunology and immunoproteomics for development of new diagnostic tools and techniques for noninvasive curative treatment of malignant tumors. He obtained his MD, PhD from Yamaguchi University in 1981 and Fogarty Fellowship at NIH from 1981 to 1983 for postdoctoral training to promote his scientific career in the Laboratory of Biochemistry, NHLBI (c/o Earl R Stadtman), NIH, USA.

Naylor S, Boston University School of Medicine, MA, USA

Nice E, Ludwig Institute for Cancer Research, Victoria, Australia Associate Professor Ed Nice is a Principal Research Fellow and Associate Member at The Ludwig Institute for Cancer Research. He has worked for the Ludwig Institute since the first branch was opened in London in 1975, and joined the branch in Melbourne, Australia, where he currently works, in 1981. His major scientific interests are in the development of techniques for the micropurification of proteins and peptides and biosensor analysis of protein- protein interactions. In particular he has applied these techniques to an understanding of signaling pathways related to cancer, including the EGF/EGFR system. He is currently working on the use of affinity-based biosensors as micropurification platforms for proteomic analysis of protein complexes. He has published over 130 peer reviewed papers in his field and is an editor on several scientific journals. He is currently Vice Chairman of the Australian Peptide Association and Steward of the Lorne Cancer Conference.

Omenn G, University of Michigan, IL, USA Gilbert Omenn is Professor of Internal Medicine, Human Genetics, and Public Health at the University of Michigan, USA. He served as Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System from 1997 to 2002. He was formerly Dean of the School of Public Health, and Professor of Medicine and Environmental Health, University of Washington, Seattle. His research interests include cancer proteomics, chemoprevention of cancers, public health genetics, science-based risk analysis, and health policy. He was principal investigator of the beta-Carotene and Retinol Efficacy Trial (CARET) of preventive agents against lung cancer and heart disease; director of the Center for Health Promotion in Older Adults; and creator of a university-wide initiative on Public Health Genetics in Ethical, Legal, and Policy Context while at the University of Washington and Fred Hutchinson Cancer Research Center. He served as Associate Director, Office of Science and Technology Policy, and Associate Director, Office of Management and Budget, in the Executive Office of the President in the Carter Administration. He is a longtime director of Amgen Inc. and of Rohm & Haas Company. He is a member of the Council and leader of the Plasma Proteome Project for the international Human Proteome Organization (HUPO). Prof. Omenn is the author of 390 research papers and scientific reviews and author/editor of 17 books. He is a member of the Institute of Medicine of the National Academy of Sciences, the American Academy of Arts and Sciences, the Association of American Physicians, and the American College of Physicians. He chaired the presidential/congressional Commission on Risk Assessment and Risk Management ("Omenn Commission"), served on the National Commission on the Environment, and chaired the NAS/NRC/IOM Committee on Science, Engineering and Public Policy. He is active in cultural and educational organizations, and is a musician and tennis player. Omenn received his B.A. from Princeton, the M.D., magna cum laude, from Harvard Medical School, and a Ph.D. in genetics from the University of Washington.

Ottens AK, University of Florida, FL, USA Dr Ottens is the Associate Director of the Center for Neuroproteomics and Biomarkers Research and an Assistant Professor of Psychiatry and Neuroscience at the McKnight Brain Institute of the University of Florida. He received his Ph.D. in Analytical Chemistry from the University of Florida, receiving the Bates Award of excellence, after which he completed his post-doctoral training in Neuroscience. Dr Ottens’ research focuses on neuroproteomics, with an interest in integrating bioanalytical science and technology (particularly analytical separations and mass spectrometry) for the characterization of protein chemistry perturbation in the brain following injury by trauma or toxic substances. He recently received a Career Award from the National Institute of Neurological Disorders and Stroke to develop new chemistry for characterization of protein proteolysis following brain injury. Dr Ottens is also presently exploring the impact of secondhand smoke as a toxic substance in the developing brain.

Petricoin EF, George Mason University, VA, USA

Qian W-J, Pacific Northwest National Laboratory, Richland, WA, USA Wei-Jun Qian received his Ph.D. in Bioanalytical Chemistry in 2002 from the University of Florida, where he received graduate fellowship awards from the American Chemical Society and Eastman Chemical Company. Following graduation, Dr Qian joined Pacific Northwest National Laboratory in Richland, Washington where he is presently a Staff Scientist in the Biological Sciences Division. Dr Qian’s current research focuses on developing integrated mass spectrometry-based approaches that enable quantitative measurements of the dynamics of proteins and protein modifications in biological and clinical applications. He is the author/co-author of more than 40 peer-reviewed publications.

Rohlff C, Oxford Genome Sciences, UK Dr Christian Rohlff received his PhD from the Department of Pharmacology at Georgetown University and is founder of Oxford Genome Sciences (OGeS). After two appointments at the National Cancer Institute he joined Oxford GlycoSciences and was appointed Director of Proteome Research Collaboration in 2001. As manager of the Proteomics Division’s commercial collaborations he gained expertise in the implementation of clinical proteomics programmes to identify novel therapeutic protein targets and protein diagnostics with many pharmaceutical companies, the FDA and academic partners. As well as being the founder of OGeS, Dr Rohlff is a founding member of the South East Health Technologies Alliance (SEHTA), which was established to promote innovation and international competitiveness in South-East England’s health technologies sector.

Singh OV, The Johns Hopkins School of Medicine, Baltimore, USA Dr Om V. Singh received his PhD in Microbial Biotechnology from the Department of Biotechnology, Indian Institute of Technology (IIT), Roorkee, India. Dr Singh is currently a researcher in the Department of Pediatrics, Johns Hopkins School of Medicine and working on proteomics of cystic fibrosis. Dr Singh’s expertise is in two-dimensional gel electrophoresis that gained access to identify novel therapeutic targets in protein trafficking machinery at sub cellular level. He brings to his research a unique combination of ‘pharmaco-interactomics’ with basic science in the search for potential therapeutic targets that can be applied to multiple diseases states. His multidisciplinary research achievements and interests from the development of industrially useful microbes to environmental health has been recognized and documented in many scientific journals.

Sippl M, Center of Applied Molecular Engineering, Salzburg, Austria

Smejkal G, Harvard University, USA Gary B. Smejkal, Senior Applications Scientist at Proteome Systems Incorporated. Dr Smejkal's Expertise is in two-dimensional gel electrophoresis. Formerly in Basic and Clinical Research at the Cleveland Clinic Foundation Departments of Cell Biology and Clinical Pathology.

Southan C, AstraZeneca R&D Mölndal, Sweden Christopher Southan is a Principle Scientist in the Department of Molecular Pharmacology AstraZeneca, Mölndal, Sweden, and Special Professor of Proteomics, School of Biosciences, University of Nottingham, UK. Prior to this he has held senior bionformatician positions in Oxford Glycosciences (2002–2004), Gemini Genomics (2001) and SmithKline Beecham (1987– 2000). Before entering industry his posts included running the Cancer Research Campaign Protein Sequencing Facility, UK (1986–1987), Research Fellow in the Charing Cross Hospital Medical School, UK (1984– 1986), a PhD from the Ludwig Maximillian University of Munich, Germany, an MSc in Virology from Reading University, UK and a BSc Hons in Biochemistry from Dundee University, UK. His current activities involve leading a group of bioinformaticians supporting drug discovery in AstraZeneca Mölndal. His background and interests include the sequence analysis of proteins, proteomics, comparative genomics, proteases and protein chromatography. He has over 70 publications, 43 of which are in PubMed, and 21 sequence patents. His name is also indexed on submissions or crossreferences for 32 Swiss-Prot sequences.

Strosberg AD, The Scripps Research Institute, Florida, USA Prof. A. Donny Strosberg is Founder, President, Chairman and Chief Executive Officer of Hybrigenics, Paris, France. Hybrigenics is a biotechnology and bioinformatics company that specializes in functional proteomics. Using automated high-throughput techniques and proprietary bioinformatics tools, Hybrigenics identifies and validates therapeutic targets for cancer treatment. Corresponding small molecules are also identified and validated in partnership with companies in the corresponding research area.Prior to co-founding Hybrigenics, Prof. Strosberg was an advisor to several major pharmaceutical companies and has co-founded several other start-up biotechnology companies. Prof. Strosberg is a specialist in the development of screening technologies especially applied to small molecules binding to membrane receptors expressed in bacteria, in yeast and in mammalian cells. He is author of over 400 peer-reviewed scientific articles and holds over thirty patents of which many are licensed to bio-pharmaceutical companies.

Thongboonkerd V, Mahidol University, Thailand

van Regenmortel MH, CNRS, Strasbourg, France Marc Van Regenmortel is an Emeritus Director in the Biotechnology School of the University of Strasbourg, France. He was born and educated in Brussels, Belgium and received his PhD degree from UCT Medical School in 1961. He held positions as professor of Virology and Microbiology at several universities in South Africa and France and was for 22 years director of the Immunochemistry laboratory at the Molecular Biology Institute in Strasbourg. He has published 15 books and over 350 papers and reviews in virology, viral taxonomy, immunochemistry and biosensor technology and is currently Editor-in-Chief of Archives of Virology, Journal of Molecular Recognition and Executive Editor of Analytical Biochemistry. He also serves on the editorial boards of Advances in Virus Research, Biologicals, Journal of Immunological Methods, Immunological Investigations, International Journal of Biochromatography, Methods and Expert Review of Proteomics.

Veenstra TD, National Cancer Institute - Frederick, MD, USA

Wright Jr GL, Eastern Virginia Medical School, VA, USA Dr Wright received the Ph.D. degree from Michigan State University in 1966. From 1966 to 1973 he as a faculty member at George Washington University and then joined the faculty at Eastern Virginia Medical School (EVMS) in 1973. In 1987, he co-founded the Virginia Prostate Center, a multidisciplinary program providing quality patient care, education, and translational research in urological diseases. Dr Wright's research focuses on the detection, identification, and characterization of biomarkers for early detection of urological cancers using both molecular and proteomic technologies. Recent efforts have demonstrated the clinical utility of mass spectral protein profiling as a potentially novel clinical assay for the early detection of cancer. Although Dr Wright has recently retired as Chairman and Professor at EVMS, he continues to be actively involved using proteomics to define the prostate cancer proteome. Dr Wright has published more than 150 original scientific papers and over 350 scientific presentations, and has 11 patents. He has been on several editorial boards, including The Prostate and Urological Oncology; and has received numerous scientific awards; most recently the EVMS Foundation Chair in Biomedical Science.

Yamada T, National Cancer Center Research Institute, Japan